The Manufacturers Life Insurance Company Has $689,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

The Manufacturers Life Insurance Company decreased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 2.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 86,977 shares of the company’s stock after selling 2,448 shares during the period. The Manufacturers Life Insurance Company’s holdings in Amneal Pharmaceuticals were worth $689,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC lifted its holdings in Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after buying an additional 169,756 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at about $520,000. Amundi bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at about $256,000. Franklin Resources Inc. increased its position in Amneal Pharmaceuticals by 4.9% in the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock valued at $778,000 after buying an additional 4,178 shares in the last quarter. Finally, Entropy Technologies LP bought a new stake in Amneal Pharmaceuticals in the 4th quarter valued at about $259,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barclays boosted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Finally, StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average target price of $11.50.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the sale, the director now directly owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. This represents a 4.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.56% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Stock Up 2.0%

Amneal Pharmaceuticals stock opened at $7.50 on Friday. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.29 and a twelve month high of $9.48. The firm has a 50 day moving average price of $7.79 and a 200-day moving average price of $8.10. The company has a market capitalization of $2.32 billion, a P/E ratio of -11.03 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The firm had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. Equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.